Cardiome drug clears European committee
June 25, 2010 by leonardzehr · Leave a Comment
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing approval for Cardiome Pharma’s (TSX:COM; NASDAQ:CRME) vernakalant, an investigational intravenous formulation for the conversion of atrial fibrillation to normal heart rhythm in adults. Granting of marketing authorization by the European Commission is expected later this year and will apply [...]
Listen to BioTuesdays 
